BLRD Research Career Scientist Award Application

BLRD 研究职业科学家奖申请

基本信息

批准号：
10514630
负责人：
Maurizio Del Poeta
金额：
--
依托单位：
NORTHPORT VA MEDICAL CENTER
依托单位国家：
美国
项目类别：
财政年份：
2020
资助国家：
美国
起止时间：
2020-10-01 至 2025-09-30
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10514630
关键词：
Acquired Immunodeficiency Syndrome Adrenal Cortex Hormones Animal Model Antifungal Agents Antifungal Therapy Aspergillus fumigatus Autoimmune Diseases Award Biological Assay Brain CD4 Positive T Lymphocytes Candida albicans Cell Count Cells Ceramides Cessation of life Clinic Clinical Collaborations Communicable Diseases Communities Containment Cryptococcal Meningitis Cryptococcosis Cryptococcus Cryptococcus neoformans Dependence Development Disease Drug Design Drug Formulations Drug resistance Educational process of instructing Effectiveness Ensure Environment Enzymes Exposure to Faculty Fungal Vaccines General Population Glucosylceramides Goals Granuloma Growth HIV Hand Host Defense Immune Evasion Immune system Immunity Immunocompromised Host Industry Infection Injections Inositol Integration Host Factors Intervention Investigation Knowledge Laboratories Lipids Lung Malignant Neoplasms Mediating Medical Medical center Molecular Morbidity - disease rate Mycoses Organ Transplantation Organism Pathogenesis Pathogenicity Pathway interactions Patients Pharmaceutical Chemistry Pharmaceutical Preparations Phenotype Physicians Population Postdoctoral Fellow Predisposition Preventive Process Research Research Personnel Resistance SPHK1 enzyme Scientist Services Source South Carolina Specificity Sphingolipids Sphingomyelins Spinal Cord Structure Students Substance abuse problem Symptoms Technology Testing The science of Mycology Therapeutic Therapeutic immunosuppression Toxic effect Toxicology Training Universities Veterans Virulence Work career chemotherapy cross reactivity design experience fungus high throughput screening immunoregulation inhibitor interest microbial microorganism interaction military service mortality multiple sclerosis treatment novel novel therapeutic intervention novel therapeutics opportunistic pathogen patient population research and development small molecule sphingomyelin synthase sphingosine 1-phosphate therapeutically effective

项目摘要

ABSTRACT I am an Infectious Diseases physician-scientist with over 28 years of experience in medical mycology. During my career, I have been working in the clinic and at the bench, teaching and training many students, post-docs and junior faculty at Duke University, the Medical University of South Carolina, and now at Stony Brook University and at the Northport VA Medical Center. My overall career goal is to bring a new antifungal in the clinic, and I am closer than ever with MicroRid Technologies Inc., a start-up company I co-founded for the research and development of new antifungal drugs. My laboratory pioneered the studies on lipid-mediated infectious diseases. My lab and my co-workers reached such a high visibility in this field that we are continuously contacted for consultant work by investigators from all over the world for lipid analysis in their favorite organisms. My studies have mostly focused on fungal infections, particularly invasive fungal infections, because they are on the rise in our Veterans and in our non-Veterans populations. As we live longer thanks to many benefits of chemo- and immunosuppressive-therapies and organ transplantations, we are also facing a rise of invasive fungal infectious diseases. Current antifungals are either fungistatic, toxic, with narrow spectrum of activity or they become resistant. New treatment strategies are needed. In addition to develop a new class of antifungal agents, the studies in my laboratory are also crucial to the understanding of the host mechanisms required for fungal containment versus fungal dissemination and disease. For these studies, I partnered with many collaborators at the VA medical centers, at various Universities, and at the industry setting, establishing fruitful and successful collaborations. The VA RCS award will allow our group to continue this great work and will provide stability to fulfill the current goals and to start new research directions. The RCS Award will also allow me to broaden my collaborative research even further, particularly with the VA physicians involved in the MVP, enhancing my research clinical enterprise, and to continue my service to the scientific community at the VA and beyond.

抽象的我是一种传染病医师科学家，拥有超过28年的医学真菌学经验。在我的职业生涯中，我一直在诊所和替补席上工作，教学和培训许多杜克大学，南卡罗来纳州医科大学的学生，毕业后和初级教职员工，现在在Stony Brook University和Northport VA医疗中心。我的整体职业目标是为了在诊所带来新的抗真菌，我比Microrid Technologies Inc.比以往任何时候都更接近我共同创立了新的抗真菌药物的初创公司。我的实验室开创了有关脂质介导的传染病的研究。我的实验室和我的同事在这一领域达到了如此高的知名度，以至于我们不断与我们联系以进行顾问工作来自世界各地的调查人员在他们最喜欢的生物中进行脂质分析。我的学习有主要专注于真菌感染，尤其是侵入性真菌感染，因为它们在在我们的退伍军人和非退伍军人人口中崛起。由于我们的寿命更长，这要归功于许多好处化学和免疫抑制性治疗和器官移植，我们也面临着侵入性真菌传染病。当前的抗真菌剂要么是燃料，有毒的，有狭窄活动范围或它们变得抗性。需要新的治疗策略。此外开发一类新的抗真菌药物，我的实验室研究也对了解真菌遏制与真菌传播所需的宿主机制和疾病。对于这些研究，我与VA医疗中心的许多合作者合作各种大学以及在行业环境中建立了富有成果和成功的合作。这 VA RCS奖将使我们的团队能够继续这项出色的工作，并将提供稳定以实现当前的目标并开始新的研究方向。 RCS奖还可以使我扩大我的进一步的协作研究，尤其是在参与MVP的VA医师时，增强我的研究临床企业，并继续为科学界服务 VA及以后。